Interleukin-6 in retinal diseases: From pathogenesis to therapy

被引:7
|
作者
Xiao, Ruihan [1 ]
Lei, Chunyan [1 ]
Zhang, Yi [1 ]
Zhang, Meixia [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Ophthalmol, Res Lab Macular Dis, Chengdu 610041, Peoples R China
关键词
Interleukin-6; Retinal diseases; Targeted-IL-6; treatment; Precision medicine; ENDOTHELIAL GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; OPEN-ANGLE GLAUCOMA; PROLIFERATIVE VITREORETINOPATHY; OXIDATIVE STRESS; AQUEOUS-HUMOR; MACULAR EDEMA; CYTOKINE EXPRESSION; T-CELLS; PROINFLAMMATORY CYTOKINES;
D O I
10.1016/j.exer.2023.109556
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Interleukin-6 (IL-6) is a pleiotropic cytokine that participates in immunomodulation, inflammation, increases vascular permeability, hematopoiesis, and stimulates cell proliferation, among other biological processes. It exerts effects primarily through the classic and trans-signaling pathways. Many studies have demonstrated that IL-6 plays a critical role in the development of retinal diseases including diabetic retinopathy, uveitis, age-related macular degeneration, glaucoma, retinal vein occlusion, central serous chorioretinopathy and proliferative vitreoretinopathy. Thus, the progressive development of drugs targeting IL-6 and IL-6 receptor may play a role in the treatment of multiple retinal diseases. In this article, we comprehensively review the IL-6's biological functions of and its mechanisms in the pathogenesis of various retinal diseases. Furthermore, we summarize the drugs targeting IL-6 and its receptor and prospect their potential application in retinal diseases, hoping to provide new ideas for the treatment of retinal diseases.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Interleukin-6 blocking therapy for COVID-19: From immune pathogenesis to clinical outcomes
    Xiao, Fan
    Wu, Ling
    Zhu, Xiaoxia
    Zhang, Lijun
    Liu, Dongzhou
    Wu, Lijun
    Zou, Hejian
    Lu, Liwei
    RHEUMATOLOGY AND IMMUNOLOGY RESEARCH, 2022, 3 (01): : 11 - 16
  • [2] Interleukin-6 and cardiovascular diseases
    Kanda, T
    Takahashi, T
    JAPANESE HEART JOURNAL, 2004, 45 (02): : 183 - 193
  • [3] Targeting interleukin-6 in pediatric rheumatic diseases
    De Benedetti, Fabrizio
    CURRENT OPINION IN RHEUMATOLOGY, 2009, 21 (05) : 533 - 537
  • [4] Interleukin-6 in the pathogenesis of posterior capsule opacification and the potential role for interleukin-6 inhibition in the future of cataract surgery
    Lewis, Aaron C.
    MEDICAL HYPOTHESES, 2013, 80 (04) : 466 - 474
  • [5] Correlation between Interleukin-6 and Thrombin-Antithrombin III Complex Levels in Retinal Diseases
    Ehrlich, Rita
    Zahavi, Alon
    Axer-Siegel, Ruth
    Budnik, Ivan
    Dreznik, Ayelet
    Dahbash, Mor
    Nisgav, Yael
    Megiddo, Elinor
    Kenet, Gili
    Weinberger, Dov
    Livnat, Tami
    CURRENT EYE RESEARCH, 2017, 42 (09) : 1269 - 1272
  • [6] Targeting interleukin-6 in inflammatory autoimmune diseases and cancers
    Yao, Xin
    Huang, Jiaqi
    Zhong, Haihong
    Shen, Nan
    Faggioni, Raffaella
    Fung, Michael
    Yao, Yihong
    PHARMACOLOGY & THERAPEUTICS, 2014, 141 (02) : 125 - 139
  • [7] Interleukin-6 in oral diseases: a review
    Nibali, L.
    Fedele, S.
    D'Aiuto, F.
    Donos, N.
    ORAL DISEASES, 2012, 18 (03) : 236 - 243
  • [8] Role of interleukin-6 in the pathogenesis of multiple myeloma
    Gadó, K
    Domján, C
    Hegyesi, H
    Falus, A
    CELL BIOLOGY INTERNATIONAL, 2000, 24 (04) : 195 - 209
  • [9] Interleukin-6 in chronic liver diseases
    Salmayenli, N
    Genç, S
    Karan, A
    Tascioglu, C
    Güler, K
    Vatansever, S
    Sivas, A
    MEDICAL SCIENCE RESEARCH, 1998, 26 (03): : 207 - 208
  • [10] Interleukin-6 and pulmonary hypertension: from physiopathology to therapy
    Xu, Wei-Jie
    Wu, Qiong
    He, Wen-Ni
    Wang, Shang
    Zhao, Ya-Lin
    Huang, Jun-Xia
    Yan, Xue-Shen
    Jiang, Rong
    FRONTIERS IN IMMUNOLOGY, 2023, 14